Category: Pharma, Life Sciences & Med Tech Players
-
Moderna, Genevant, Arbutus settle global mRNA patent infringement dispute
Moderna could have to pay up to $2.25 billion as part of the settlement agreement, but remains confident it will close 2026 with up to $5 billion in cash and cash equivalents as a result of the deal.
-
Novo Nordisk targets Canadian pharma giant Apotex in new oral semaglutide patent infringement suit
Novo Nordisk has sued Canada’s Apotex in the United States District Court for the District of New Jersey over the alleged infringement of six patents related to its oral weightloss drug Rybelsus.
-
New COVID-19 vaccine patent suit: BioNTech v. Moderna
BioNTech has sued Moderna in the United States District Court for the District of Delaware, alleging that the defendant’s most profitable vaccine mNexspike infringes on its key RNA technology.
-
Astellas settles parallel bladder treatment patent suits against India’s Lupin, Zydus: licensing deals worth combined $210 million
Japanese pharmaceutical giant Astellas has signed patent licensing agreements with Indian rivals Lupin and Zydus worth over $210 million, ending all ongoing litigation between the companies in the District of Delaware.
-
Appeals court persuades GrĂĽnenthal to drop unfair competition law injunctions (obtained in parallel to patent PIs) against Abdi Farma
GrĂĽnenthal had won two different types of injunctions against Amdi Farma over painkillers: a patent PI (on appeal) and unfair competition PIs, which have just been lifted.
-
Novo Nordisk files fresh semaglutide patent infringement suit in District of Delaware
Novo Nordisk has sued telehealth medication provider Hims & Hers over the infringement of one of its semaglutide patents, as the company faces headwinds over its weightloss drugs for the first time in nearly a decade.
-
UPC’s Hague LD grants Abbott two preliminary injunctions, assumes long-arm jurisdiction (Spain) over German defendants, clarifies urgency requirement
The Unified Patent Court’s Hague LD has provided clarifications on long-arm jurisdiction and urgency that have applicabiliy beyond these two cases.
-
Cross-border injunctions “have their place” but can be “big ask”: Sandoz Global Head of IP Julia Pike
There is a place for cross-border injunctions, but in more nuanced cases (such as Regeneron v. Advanz) it’s a “big ask” for one country to take that decision itself on behalf of all those other countries, the company’s Global Head of IP Julia Pike has told ip fray.
-
Roche’s Genentech, Organon, China’s Henlius settle major pertuzumab biosimilar litigation in U.S., UPC, NL, and Brazil (where it was most advanced)
A favorable validity decision by the Brazilian patent office and evidence preservation in the UPC contributed to this important biosimilar settlement.
-
“Principles of good litigation are universal”: Novo Nordisk Associate General Counsel Raquel Frisardi
“Whether you are litigating a contract, patent infringement, or a crime – there are certain behaviors as a litigator that get you better results, and I think those are very universal,” Raquel Frisardi told ip fray in an interview during Kisaco’s Patent Litigation Europe Summit.